Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful conscientiously but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. My first CytoDyn post, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set away the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a very marketing picture in the Uptick Newswire employment interview that I came away with an inadequate opinion of the business.

Irony of irony, the poor opinion of mine of the business has grown steadily, although the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the technology as well as associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) and also the first new drug program endorsement ($five million), and also royalty payments of five % of net sales after commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and many therapies, it’s this single treatment as well as a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on its website (below) shows an energetic business with diverse interests albeit centered on leronlimab, several disease sorts, multiple presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really start of my interest in this particular company. Judging with the multiples of a huge number of various responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *